HC Wainwright Has Positive View of OKYO Pharma Q1 Earnings

Key Points

• HC Wainwright has raised its Q1 2026 earnings per share estimate for OKYO Pharma from ($0.04) to ($0.02), maintaining a "Buy" rating with a price target of $7.00.
• The consensus estimate for OKYO Pharma's full-year earnings is currently (0.17) per share, with additional expectations of continued losses in subsequent quarters.
• Institutional investors have recently increased their positions in OKYO Pharma, with notable acquisitions from Wealth Enhancement Advisory Services and Dauntless Investment Group.

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) - Investment analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for shares of OKYO Pharma in a research note issued to investors on Tuesday, September 23rd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.02) per share for the quarter, up from their previous estimate of ($0.04). HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for OKYO Pharma's current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for OKYO Pharma's Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.19) EPS.

Several other analysts have also recently issued reports on the stock. Wall Street Zen raised shares of OKYO Pharma to a "hold" rating in a research note on Saturday, August 9th. Zacks Research upgraded OKYO Pharma to a "hold" rating in a research report on Tuesday, September 16th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $7.00.

OKYO Pharma Stock Performance

Shares of OKYO stock opened at $2.11 on Thursday. The stock's fifty day moving average is $2.52 and its two-hundred day moving average is $2.03. OKYO Pharma has a fifty-two week low of $0.90 and a fifty-two week high of $3.35.

Institutional Investors Weigh In On OKYO Pharma

A number of institutional investors have recently made changes to their positions in OKYO. Wealth Enhancement Advisory Services LLC acquired a new position in shares of OKYO Pharma in the 2nd quarter worth approximately $28,000. Dauntless Investment Group LLC acquired a new position in OKYO Pharma during the first quarter worth $2,526,000. Finally, FNY Investment Advisers LLC purchased a new position in shares of OKYO Pharma during the first quarter worth $25,000. 2.97% of the stock is currently owned by institutional investors and hedge funds.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.